Ranibizumab, Lucentis®)

Ranibizumab, Lucentis®)

Clinical Development RFB002 (Ranibizumab, Lucentis®) Clinical Trial Protocol CRFB002DDE26 / NCT02366468 A 12-months, randomized, VA-assessor blinded, multicenter, controlled phase IV trial to investigate non- inferiority of two treatment algorithms (discretion of the investigator vs. pro re nata) of 0.5 mg ranibizumab in patients with visual impairment due to diabetic macula edema Authors: Document type: Clinical Trial Protocol EUDRACT number: 2014-002854-37 Version number: v01 (incl. Amendment 01) Development phase: IV Release date: 18-04-2016 Property of Novartis Confidential May not be used, divulged, published, or otherwise disclosed without the consent of Novartis NOVDD Template Version 03-Feb-2012 Novartis Confidential Page 2 Clinical Trial Protocol (Version No. 01) Protocol No. CRFB002DDE26 Table of contents Table of contents ................................................................................................................. 2 List of tables ........................................................................................................................ 5 List of figures ...................................................................................................................... 5 List of abbreviations ............................................................................................................ 6 Glossary of terms ................................................................................................................. 8 Summary of protocol amendments ...................................................................................... 9 Protocol synopsis ............................................................................................................... 12 1 Introduction ....................................................................................................................... 16 1.1 Background ............................................................................................................ 16 1.2 Purpose .................................................................................................................. 17 2 Study objectives ................................................................................................................. 17 2.1 Primary and key secondary objectives .................................................................. 17 2.1.1 Primary objective .................................................................................. 17 2.1.2 Secondary objectives ............................................................................. 17 17 3 Investigational plan ........................................................................................................... 18 3.1 Study design........................................................................................................... 18 3.2 Rationale of study design ....................................................................................... 19 3.3 Rationale of dose/regimen, route of administration and duration of treatment ..... 20 3.4 Rationale for choice of comparator ....................................................................... 21 3.5 Purpose and timing of interim analyses/design adaptations .................................. 21 3.6 Risks and benefits .................................................................................................. 21 4 Population .......................................................................................................................... 22 4.1 Inclusion criteria .................................................................................................... 22 4.2 Exclusion criteria ................................................................................................... 23 5 Treatment ........................................................................................................................... 26 5.1 Protocol requested treatment ................................................................................. 26 5.1.1 Investigational treatment ....................................................................... 26 5.1.2 Additional study treatment .................................................................... 26 5.2 Treatment arms ...................................................................................................... 26 5.3 Treatment assignment, randomization ................................................................... 26 5.4 Treatment masking ................................................................................................ 27 5.5 Treating the patient ................................................................................................ 27 5.5.1 Patient numbering ................................................................................. 27 5.5.2 Dispensing the investigational treatment .............................................. 27 Novartis Confidential Page 3 Clinical Trial Protocol (Version No. 01) Protocol No. CRFB002DDE26 5.5.3 Handling of study treatment .................................................................. 28 5.5.4 Instructions for prescribing and taking study treatment ........................ 30 5.5.5 Permitted dose adjustments and interruptions of study treatment ........ 30 5.5.6 Rescue medication ................................................................................ 30 5.5.7 Concomitant treatment .......................................................................... 31 5.5.8 Prohibited Treatment ............................................................................. 31 5.5.9 Discontinuation of study treatment and premature patient withdrawal ............................................................................................. 31 5.5.10 Emergency breaking of treatment assignment ...................................... 32 5.5.11 Study completion and post-study treatment .......................................... 32 5.5.12 Early study termination ......................................................................... 33 6 Visit schedule and assessments ......................................................................................... 33 6.1 Information to be collected on screening failures.................................................. 37 6.2 Patient demographics/other baseline characteristics ............................................. 37 6.3 Treatment exposure and compliance ..................................................................... 38 6.4 Efficacy .................................................................................................................. 38 6.4.1 Best corrected visual acuity .................................................................. 38 6.4.2 Optical Coherence Tomography ........................................................... 39 6.4.3 Color Fundus Photography .................. 39 6.4.4 Appropriateness of efficacy assessments .............................................. 40 6.5 Safety ..................................................................................................................... 40 6.5.1 Physical Examination ............................................................................ 40 6.5.2 Vital signs.............................................................................................. 40 6.5.3 Height and Weight ................................................................................ 40 6.5.4 Laboratory evaluations .......................................................................... 40 6.5.5 Pregnancy and assessments of fertility ................................................. 40 6.5.6 Eye-specific safety monitoring ............................................................. 40 6.5.7 Gonioscopy ........................................................................................... 42 6.5.8 Hematology ........................................................................................... 42 6.5.9 Clinical chemistry ................................................................................. 42 6.5.10 Urinalysis .............................................................................................. 42 6.5.11 Electrocardiogram (ECG) ..................................................................... 42 6.5.12 Appropriateness of safety measurements .............................................. 42 6.6 Other assessments .................................................................................................. 42 6.6.1 Resource utilization ............................................................................... 42 43 Novartis Confidential Page 4 Clinical Trial Protocol (Version No. 01) Protocol No. CRFB002DDE26 6.6.3 Pharmacokinetics .................................................................................. 43 6.6.4 Pharmacogenetics (optional) ................................................................. 43 6.6.5 Other biomarkers ................................................................................... 43 43 43 44 7 Safety monitoring .............................................................................................................. 44 7.1 Adverse events ....................................................................................................... 44 7.2 Serious adverse event reporting ............................................................................. 46 7.3 Liver safety monitoring ........................................................................................

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    61 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us